DE60303961T2 - Modifizierte saccharide, deren konjugate sowie deren herstellung - Google Patents

Modifizierte saccharide, deren konjugate sowie deren herstellung Download PDF

Info

Publication number
DE60303961T2
DE60303961T2 DE60303961T DE60303961T DE60303961T2 DE 60303961 T2 DE60303961 T2 DE 60303961T2 DE 60303961 T DE60303961 T DE 60303961T DE 60303961 T DE60303961 T DE 60303961T DE 60303961 T2 DE60303961 T2 DE 60303961T2
Authority
DE
Germany
Prior art keywords
saccharide
formula
alkyl
modified
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60303961T
Other languages
German (de)
English (en)
Other versions
DE60303961D1 (de
Inventor
Aldo Giannozzi
Giovanni Averani
Francesco Norelli
Paolo Costantino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Publication of DE60303961D1 publication Critical patent/DE60303961D1/de
Application granted granted Critical
Publication of DE60303961T2 publication Critical patent/DE60303961T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60303961T 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung Expired - Lifetime DE60303961T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220198 2002-08-30
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Publications (2)

Publication Number Publication Date
DE60303961D1 DE60303961D1 (de) 2006-05-04
DE60303961T2 true DE60303961T2 (de) 2006-10-26

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303961T Expired - Lifetime DE60303961T2 (de) 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN101863998B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
BRPI0611447A2 (pt) * 2005-05-06 2010-09-08 Stockholm University imunógenos para vacinas contra meningite a
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
SA114350400B1 (ar) * 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
PL2493498T3 (pl) * 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
HUE038511T2 (hu) * 2015-04-23 2018-10-29 Synaffix Bv (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás
RU2758090C2 (ru) * 2016-03-15 2021-10-26 Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. Новые конъюгаты полисахарида с белком и способ их получения
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20190121330A (ko) * 2017-02-24 2019-10-25 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
MX2021010555A (es) * 2019-03-08 2022-04-06 Glaxosmithkline Biologicals Sa Derivados carbocíclicos y derivados conjugados de los mismos y su uso en vacunas.
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
ES2067854T3 (es) * 1990-03-15 1995-04-01 Tanabe Seiyaku Co Polisulfato de derivado de ciclodextrina y procedimiento para preparar el mismo.
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
CA2189356A1 (en) * 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1998031393A2 (en) * 1997-01-21 1998-07-23 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
JP4182269B2 (ja) * 1997-08-08 2008-11-19 ベーリングウエルケ、アクティエンゲゼルシャフト 生体分子のポリサッカライド接合体
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
DK1777236T3 (en) 2002-03-26 2017-02-27 Glaxosmithkline Biologicals Sa MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
DK1534342T3 (da) 2006-07-10
US20150166593A1 (en) 2015-06-18
ATE319481T1 (de) 2006-03-15
BR0314089A (pt) 2005-11-16
CA2497167C (en) 2011-07-12
NZ538703A (en) 2006-09-29
CA2497167A1 (en) 2004-03-11
JP2006511465A (ja) 2006-04-06
JP5268222B2 (ja) 2013-08-21
DE60303961D1 (de) 2006-05-04
AU2003260921B2 (en) 2008-03-06
RU2008150551A (ru) 2010-06-27
US20060263390A1 (en) 2006-11-23
GB0220198D0 (en) 2002-10-09
EP1534342B1 (en) 2006-03-08
WO2004019992A1 (en) 2004-03-11
AU2003260921A1 (en) 2004-03-19
ES2260682T3 (es) 2006-11-01
JP2012017342A (ja) 2012-01-26
CN101863998A (zh) 2010-10-20
CN1688343B (zh) 2010-09-08
CN101863998B (zh) 2012-08-29
US8895516B2 (en) 2014-11-25
JP5314745B2 (ja) 2013-10-16
RU2531909C2 (ru) 2014-10-27
EP1534342A1 (en) 2005-06-01
CN1688343A (zh) 2005-10-26
MXPA05002315A (es) 2005-06-08
RU2005108992A (ru) 2005-11-10

Similar Documents

Publication Publication Date Title
US8895516B2 (en) Modified saccharides, conjugates thereof, and their manufacture
EP1777236B1 (en) Modified saccharides having improved stability in water for use as a medicament
DE60314756T2 (de) Membranvesikel (omv) mit verbesserten eigenschaften
EP2216044B1 (en) Capsular polysaccharide solubilisation and combination vaccines
EP1506007B1 (en) Mucosal combination vaccines for bacterial meningitis
CN100491403C (zh) 具有改善的水中稳定性的修饰的糖类
AU2003216633B2 (en) Modified saccharides having improved stability in water
AU2014218428A1 (en) Capsular polysaccharide solubilisation and combination vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIEN, IT